A Food and Drug Administration advisory panel met to discuss regulatory approval for the Alzheimer's drug, Leqembi.

<div class="block">A Food and Drug Administration advisory panel met to discuss regulatory approval for the Alzheimer&#39;s drug, Leqembi.</div>

Closing Bell

FDA Panel Discusses Approval of Alzheimer's Drug

And elsewhere. An FDA advisory panel met this morning to discuss regulatory approval of the Alzheimer's drug Lemine. The FDA granted the drug accelerated approval back in January after research showed its effectiveness in removing toxic plaques from the brain. Late stage trials show that the drug slowed cognitive decline by 27% in early Alzheimer's patients and the company behind the drug Biogen trading today. Take a look. It is higher on the news. Well, the NASDAQ halted trading this morning as the FDA review took place but the US Medicare health plan says it's going to pay for the treatment of doctors participate in a health agency database that would track how the drug works. The FDA is expected to make its decision on the approval by July six. And if it does go through the drug would be the first of its class of drugs to achieve a regulatory approval. Well, according to the Alzheimer's Association, more than six million Americans are affected by the disease.